Traders should monitor for immediate downward pressure on IMA shares due to significant dilution from deeply discounted warrants. The low exercise price of $0.001 means near-certain exercise, effectively adding ~5.77 million new shares at minimal cost, which could weigh on valuation despite the capital infusion.
Price Chart
Executive Summary
ImageneBio (IMA) announced a $30 million private placement led by Coastlands Capital, with proceeds aimed at advancing its IMG-007 program in alopecia areata and atopic dermatitis. The offering includes pre-funded warrants exercisable at $0.001 per share, representing immediate economic dilution to existing shareholders.
Key Financial Metrics
Key Facts
- ImageneBio raised approximately $30 million in a private placement through pre-funded warrants.
- Pre-funded warrants for 5,770,335 shares were sold at $5.199 per unit, exercisable at $0.001 per share.
- Proceeds will fund development of IMG-007 in alopecia areata and late-stage atopic dermatitis trials.
- The placement was led by new investor Coastlands Capital, with participation from Trails Edge Capital, Omega Funds, and OrbiMed.
- Shares underlying the warrants are unregistered and subject to resale registration rights.
Financial Impact
Approximately $30 million in gross proceeds, with issuance of 5.77 million pre-funded warrants, creating immediate dilution risk.
Risk Factors
- High dilution from pre-funded warrants with nominal exercise price
- Market conditions may pressure share price ahead of warrant settlement
- Clinical timelines for IMG-007 remain uncertain despite funding
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3272360 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 7, 2026 8w ago | EFFECT | $5.69 $4.85 | ▲ +14.76% | ▲ +14.37% | $4.60 (+19.16%) |
Jun 26, 2026 14w ago | 8-K | $6.07 $5.59 | ▼ −7.91% | ▼ −7.63% | $4.60 (−24.22%) |
Apr 30, 2026 22w ago | DEFA14A | $5.66 $5.47 | ▼ −3.36% | ▼ −8.62% | $4.60 (−18.73%) |
Apr 13, 2026 24w ago | 8-K | $6.05 $5.61 | ▲ +7.27% | ▲ +15.00% | $4.60 (+23.97%) |
Apr 13, 2026 24w ago | Press Release | $6.05 $5.61 | ▲ +7.27% | ▲ +15.00% | $4.60 (+23.97%) |
Apr 6, 2026 25w ago | EFFECT | $4.55 $5.72 | ▲ +25.60% | ▲ +16.62% | $4.60 (+1.10%) |
Mar 17, 2026 28w ago | Press Release | $5.83 $5.78 | ▼ −0.77% | ▼ −6.82% | $4.60 (−21.03%) |
Mar 10, 2026 29w ago | Press Release | $6.07 $4.57 | ▼ −24.71% | ▼ −24.56% | $4.60 (−24.22%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access